SCHEMBL487698

SCHEMBL487698

CC(=O)OCC(COP(=O)(O)OCCNCCCCCC1SC[C@@H]2NC(=O)N[C@H]12)OC(C)=O.CCN(CC)CC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLCD1 P51178 1/20 0.44
▸ F2 P00734 1/20 0.42
▸ PRSS1 P07477 1/20 0.42
▸ PRSS2 P07478 1/20 0.42
▸ PRSS3 P35030 1/20 0.42
▸ TPSAB1 Q15661 1/20 0.42
▸ CNR2 P34972 2/20 0.41
▸ TDP1 Q9NUW8 5/20 0.41
▸ CNR1 P21554 3/20 0.41
▸ HLCS P50747 5/20 0.41
▸ HPSE Q9Y251 1/20 0.40
▸ MEN1 O00255 1/20 0.38
▸ ABL1 P00519 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ IDE P14735 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ RIN1 Q13671 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1270689 1.00 PLCD1 (0.44) PLCD1F2PRSS1PRSS2PRSS3
SCHEMBL20500226 0.95 PLCD1 (0.48) PLCD1F2PRSS1PRSS2PRSS3
SCHEMBL2028171 0.91 PLCD1 (0.55) PLCD1F2PRSS1PRSS2PRSS3
SCHEMBL486900 0.90 F2 (0.53) PLCD1F2PRSS1PRSS2PRSS3
SCHEMBL3614161 0.86 PLCD1 (0.59) PLCD1F2PRSS1PRSS2PRSS3
SCHEMBL486814 0.85 PLCD1 (0.56) PLCD1F2PRSS1PRSS2PRSS3
SCHEMBL20500280 0.82 TDP1 (0.43) PLCD1F2PRSS1PRSS2PRSS3
SCHEMBL20500246 0.81 PLCD1 (0.44) PLCD1F2PRSS1PRSS2PRSS3
SCHEMBL2028172 0.79 F2 (0.51) PLCD1F2PRSS1PRSS2PRSS3
SCHEMBL28352827 0.79 TDP1 (0.50) PLCD1F2PRSS1PRSS2PRSS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2410991-A1 ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS SDG, INC. (an Ohio Corporation ) (US) 2012-02-01 — — EP claimed
WO-2010111271-A1 ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS SDG, INC. (AN OHIO CORPORATION) (US) 2010-09-30 — — WO claimed
EP-2205217-A1 ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS SDG, INC. (an Ohio Corporation ) (US) 2010-07-14 — — EP claimed
WO-2009042945-A1 ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS SDG, INC. (AN OHIO CORPORATION ) (US) 2009-04-02 — — WO claimed
EP-2410991-A1 ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS SDG, INC. (an Ohio Corporation ) (US) 2012-02-01 — — EP disclosed
WO-2011022396-A1 LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL SDG, INC. (US) 2011-02-24 — — WO disclosed
WO-2010111271-A1 ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS SDG, INC. (AN OHIO CORPORATION) (US) 2010-09-30 — — WO disclosed
EP-2205217-A1 ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS SDG, INC. (an Ohio Corporation ) (US) 2010-07-14 — — EP disclosed
WO-2009042945-A1 ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS SDG, INC. (AN OHIO CORPORATION ) (US) 2009-04-02 — — WO disclosed
EP-1883394-A2 LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL SDG, Inc. (US) 2008-02-06 — — EP disclosed
EP-1883395-A2 LIPID CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL SDG, Inc. (US) 2008-02-06 — — EP disclosed
WO-2006127361-A2 LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL SDG, INC. (US) 2006-11-30 — — WO disclosed
WO-2006127360-A2 LIPID CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL SDG, INC. (US) 2006-11-30 — — WO disclosed
Send feedback